TAB 1. Patient demographics and disease characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n (% of n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>61 (65.0)</td>
</tr>
<tr>
<td>Sex</td>
<td>60 (65.0)</td>
</tr>
<tr>
<td>IPI score</td>
<td>21 (45.7)</td>
</tr>
<tr>
<td>Baseline LDH</td>
<td>126 (126)</td>
</tr>
</tbody>
</table>

*HGBL: high-grade B-cell lymphoma; MCL: mantle cell lymphoma; PMBCL: primary mediastinal B-cell lymphoma; tFL: transitional cell lymphoma.

*Exclusion criteria: prior CD19 CAR therapy.

**Eligibility:**
- 2-6 years of age
- NHL
- Lymphocyte count decreased, and anemia

**TREATMENT:**
- CB010 manufactured from a donor with at least 4 matched HLA alleles.
- CB010 PK profile was independent of dose level.
- Onset of CRS: Onset of FOG: Onset of H Svg:
- Median duration of CR was 6.7 months for all patients.
- Median duration of CR was 6.7 months for all patients.
- Median duration of CR was 6.7 months for all patients.
- Median duration of CR was 6.7 months for all patients.
- Median duration of CR was 6.7 months for all patients.

**SAFETY AND TOLERABILITY:**
- TEAEs associated with CB010 infusion:
- TEAEs associated with CB010 infusion:
- TEAEs associated with CB010 infusion:
- TEAEs associated with CB010 infusion:
- TEAEs associated with CB010 infusion:

**Efficacy:**
- CB010 dose response:
- CB010 dose response:
- CB010 dose response:
- CB010 dose response:
- CB010 dose response:

**HLA and association with PFS:**
- Median PFS (95% CI): Median PFS (95% CI):
- Median PFS (95% CI):
- Median PFS (95% CI):
- Median PFS (95% CI):

**IMPACT OF HLA ON CB010 PK:**
- CB010 infusion:
- CB010 infusion:
- CB010 infusion:
- CB010 infusion:
- CB010 infusion:

**CONCLUSIONS:**
- CB010 dose response:
- CB010 dose response:
- CB010 dose response:
- CB010 dose response:
- CB010 dose response:

**TRANSLATIONAL ANALYSIS:**
- Circulating tumor DNA
- Circulating tumor DNA
- Circulating tumor DNA
- Circulating tumor DNA
- Circulating tumor DNA

**METHODS:**
- Primary endpoints:
- Secondary and exploratory endpoints:

**STUDY POPULATION:**
- Overall: 46 patients with aggressive B-cell lymphoma.
- IPI score: 23.0+ (IPI score:
- IPI score:
- IPI score:
- IPI score:
- IPI score:

**KEY TRIAL ENDS:**
- Primary endpoints:
- Secondary and exploratory endpoints:

**BACKGROUND:**
- Treatment failure of conventional therapies in NHL.
- New advances in autologous CAR therapy.
- Recent advances in autologous CAR therapy.